Business Description
Nectar Lifesciences Ltd
ISIN : US63975T1051
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.59 | |||||
Debt-to-EBITDA | 3.68 | |||||
Interest Coverage | 1.05 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 2.01 | |||||
Beneish M-Score | -3 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3 | |||||
3-Year EBITDA Growth Rate | 40.2 | |||||
3-Year Book Growth Rate | 0.2 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 24.86 | |||||
14-Day RSI | 33.19 | |||||
6-1 Month Momentum % | -10.95 | |||||
12-1 Month Momentum % | 25.17 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.32 | |||||
Quick Ratio | 0.59 | |||||
Cash Ratio | 0.02 | |||||
Days Inventory | 183.65 | |||||
Days Sales Outstanding | 70.77 | |||||
Days Payable | 97.59 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 12.95 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 18.42 | |||||
Operating Margin % | 5.85 | |||||
Net Margin % | 0.37 | |||||
FCF Margin % | 11.87 | |||||
ROE % | 0.58 | |||||
ROA % | 0.28 | |||||
ROIC % | 1.67 | |||||
ROC (Joel Greenblatt) % | 7.82 | |||||
ROCE % | 8.91 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 144.48 | |||||
PE Ratio without NRI | 144.48 | |||||
Shiller PE Ratio | 24.2 | |||||
Price-to-Owner-Earnings | 8.72 | |||||
PS Ratio | 0.53 | |||||
PB Ratio | 0.82 | |||||
Price-to-Tangible-Book | 0.85 | |||||
Price-to-Free-Cash-Flow | 4.48 | |||||
Price-to-Operating-Cash-Flow | 3.89 | |||||
EV-to-EBIT | 13.29 | |||||
EV-to-EBITDA | 8.62 | |||||
EV-to-Revenue | 0.9 | |||||
EV-to-FCF | 7.63 | |||||
Price-to-Projected-FCF | 0.44 | |||||
Price-to-Graham-Number | 2.56 | |||||
Price-to-Net-Current-Asset-Value | 5.11 | |||||
Earnings Yield (Greenblatt) % | 7.52 | |||||
FCF Yield % | 22.32 | |||||
Forward Rate of Return (Yacktman) % | 9.32 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Nectar Lifesciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 198.193 | ||
EPS (TTM) ($) | 0.004 | ||
Beta | 1.29 | ||
Volatility % | 44.8 | ||
14-Day RSI | 33.19 | ||
14-Day ATR ($) | 0.000037 | ||
20-Day SMA ($) | 0.358 | ||
12-1 Month Momentum % | 25.17 | ||
52-Week Range ($) | 0.266 - 0.54 | ||
Shares Outstanding (Mil) | 224.26 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nectar Lifesciences Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nectar Lifesciences Ltd Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Nectar Lifesciences Ltd Frequently Asked Questions
What is Nectar Lifesciences Ltd(LUX:NECLF)'s stock price today?
When is next earnings date of Nectar Lifesciences Ltd(LUX:NECLF)?
Does Nectar Lifesciences Ltd(LUX:NECLF) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |